Research programme: colour vision defects gene therapy - AGTC

Drug Profile

Research programme: colour vision defects gene therapy - AGTC

Alternative Names: ACHM A3; ACHM CNGA3; AGTC-402; rAAV2tYF-PR.1-hCNGA3

Latest Information Update: 28 Jun 2017

Price : $50

At a glance

  • Originator Applied Genetic Technologies Corporation
  • Developer Applied Genetic Technologies Corporation; Michigan State University; University of Pennsylvania
  • Class Eye disorder therapies; Gene therapies
  • Mechanism of Action Gene transference
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Colour vision defects
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Preclinical Colour vision defects
  • No development reported Glaucoma

Most Recent Events

  • 15 Jun 2017 Preclinical trials in Colour vision defects in Israel (Subconjunctival) before June 2017
  • 15 Jun 2017 Preclinical data in Colour vision defects released by Applied Genetic Technologies Corporation
  • 19 Oct 2016 Applied Genetic Technologies Corporation files an IND application with the US FDA for Colour vision defects
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top